APGE
Income statement / Annual
Last year (2023), Apogee Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Apogee Therapeutics, Inc.'s net income was -$83.99 M.
See Apogee Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
| Period Ended |
12/31/2023 |
12/31/2022 |
| Operating Revenue |
$0.00
|
$0.00
|
| Cost of Revenue |
$0.00 |
$0.00 |
| Gross Profit |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
| Research and Development
Expenses |
$68.42 M
|
$27.79 M
|
| General & Administrative
Expenses |
$24.58 M
|
$2.94 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$24.58 M
|
$2.94 M
|
| Other Expenses |
$0.00 |
$0.00 |
| Operating Expenses |
$93.00 M |
$30.73 M |
| Cost And Expenses |
$93.00 M |
$30.73 M |
| Interest Income |
$9.02 M |
$92,000.00 |
| Interest Expense |
$0.00 |
$9.15 M |
| Depreciation &
Amortization |
$9.02 M
|
$33.52 M
|
| EBITDA |
-$83.99 M
|
$0.00
|
| EBITDA Ratio |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
| Total Other
Income/Expenses Net |
$9.02 M
|
-$9.06 M
|
| Income Before Tax |
-$83.99 M |
-$39.79 M |
| Income Before Tax Ratio
|
0
|
0
|
| Income Tax Expense |
$0.00 |
-$33,520.00 |
| Net Income |
-$83.99 M |
-$39.79 M |
| Net Income Ratio |
0 |
0 |
| EPS |
-3.36 |
-0.79 |
| EPS Diluted |
-3.36 |
-0.79 |
| Weighted Average Shares
Out |
$25.01 M
|
$50.67 M
|
| Weighted Average Shares
Out Diluted |
$25.01 M
|
$50.67 M
|
| Link |
|
|
